Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

Part of paid clinical trials in Glendale, Arizona.

Sponsor
Hanmi Pharmaceutical Company Limited
Study ID
NCT07527650
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • HM15275 — DRUG
    HM15275 is a sterile solution for subcutaneous injection, supplied pre-filled syringes.
  • Placebo of HM15275 — DRUG
    A sterile, matching solution supplied in pre-filled syringes.

Study Details

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

Key Dates

Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
Sep 30, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: HM15275
    Participants will receive HM15275 via subcutaneous (SC) injection.
  • Placebo Comparator: Placebo of HM15275
    Participants will receive placebo of HM15275 via subcutaneous (SC) injection.

Primary Outcome Measure

Change in Glycated Hemoglobin (HbA1c) [ Time Frame: Up to 41 weeks ]

Central Contacts

Locations (10)

FacilityCityStateZIPSite coordinators
Lenzmeier Family MedicineGlendaleArizona85308
Thomas Lenzmeier (PRINCIPAL_INVESTIGATOR)
Desert Clinical ResearchMesaArizona85123
Gerald Shockey (PRINCIPAL_INVESTIGATOR)
AdventHealth Translational Research InstituteOrlandoFlorida32804
Richard Edwin Pratley (PRINCIPAL_INVESTIGATOR)
The South Bend ClinicSouth BendIndiana46617
Rita Schmid (PRINCIPAL_INVESTIGATOR)
Jefferson City Medical CenterJefferson CityMissouri65109
Benjamin Cook (PRINCIPAL_INVESTIGATOR)
Clay Platte Family MedicineKansas CityMissouri64151
Scott Kuennen (PRINCIPAL_INVESTIGATOR)
Methodist Physicians ClinicFremontNebraska68025
Thomas Wolf (PRINCIPAL_INVESTIGATOR)
Santa Rosa Medical Centers of NevadaLas VegasNevada89119
Syed Pervaiz (PRINCIPAL_INVESTIGATOR)
Lucas Research, Inc.Morehead CityNorth Carolina28557
Kathryn Jean Lucas (PRINCIPAL_INVESTIGATOR)
Olympus Family MedicineSalt Lake CityUtah84117
Jared Probst (PRINCIPAL_INVESTIGATOR)

Find similar trials in Glendale, AZ

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Lenzmeier Family Medicine· Glendale, AZDesert Clinical Research· Mesa, AZAdventHealth Translational Research Institute· Orlando, FLThe South Bend Clinic· South Bend, INJefferson City Medical Center· Jefferson City, MOClay Platte Family Medicine· Kansas City, MO

Related Studies